Objective:

To evaluate the efficacy of the MST-focused group treatment (Warrior Renew) compared to an active control group for the treatment of PTSD symptoms associated with MST in veterans.

Approach:

Key Findings:

• Warrior Renew demonstrated significant improvement in PTSD symptoms, psychiatric symptoms, posttraumatic cognitions, optimism, and self-esteem.
• The intervention showed medium to large effect sizes (Cohen d = 0.59 to 2.07) for PTSD symptom improvement.
• Sustained improvements were observed 12 months after baseline measurement in a longitudinal trial.
• An 8-session condensed version of Warrior Renew also showed efficacy in trials, including one via telehealth.

Interpretation:

Warrior Renew is a promising MST-focused group treatment for women veterans, with acceptable safety and significant efficacy in reducing PTSD symptoms.

Limitations:

• Warrior Renew has not been evaluated in an RCT with both men and women.
• The study's recruitment faced challenges, particularly in initial men cohorts.

Conclusion:

The study aims to evaluate the efficacy of MST-focused treatments in veterans, addressing a significant gap in PTSD treatment for MST survivors.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.